Y-mAbs Therapeutics 2024年第四季度GAAP每股收益$(0.15)低于预测$(0.12),销售额$26.50M低于预测$27.29M

财报速递2025-03-04
Y-mAbs Therapeutics(NASDAQ: YMAB)报告每股亏损$(0.15),低于分析师共识预期亏损$(0.12) 25%。与去年同期亏损$(0.02)每股相比,这一亏损增加了650%。公司报告季度销售额为$26.50百万,低于分析师共识预期的$27.29百万,差幅为2.91%。这比去年同期的$23.36百万销售额增长了13.41%。

以上内容来自Benzinga Earnings专栏,原文如下:

Y-mAbs Therapeutics (NASDAQ:YMAB) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.12) by 25 percent. This is a 650 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $26.50 million which missed the analyst consensus estimate of $27.29 million by 2.91 percent. This is a 13.41 percent increase over sales of $23.36 million the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法